Kornimate/medical-research-clean huggingface dataset:
superior vena caval obstruction (svco) - management and outcome

Conditions: Superior Vena Cava Syndrome

Summary: all patients with symptomatic malignant svco deemed suitable for treatment either with radiation therapy or by stenting will be eligible. they will receive whichever treatment is deemed most clinically appropriate. symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.


Eligibility criteria:
inclusion criteria: * symptomatic clinical and radiological diagnosis of superior vena caval obstruction. * underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.
idea-033 three months dose finding in oa followed by idea-033 three months extension in oa

Conditions: Osteoarthritis; Knee

Summary: the study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety. the study is designed with three dose levels and one placebo control.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of oa in at least one knee for a minimum of 6 months * aged 18-75 years old * eligible subjects must have used an oral or rectal nsaid on at least three days per week during the three months before screening or on at least 25 of the 30 days before screening, but be dissatisfied with the current nsaid treatment * at baseline visit womac pain subscale at least 40 mm, and at least 15 mm greater than at the screening visit in the index knee * radiographic evidence consistent with oa criteria of grade 2 or 3 according to kellgren \& lawrence in the index knee. radiographs mus have been taken during the 6 months before baseline. * american college of rheumatology (acr) functional class i, ii or iii exclusion criteria: * intraarticular injections or arthroscopy of the index knee within 3 months prior to screening, or planned during the study * history, physical examinations or radiographs suggestive of other rhematic diseases * known hypersensitivity or contraindication to ketoprofen; nsaid idiosyncrasy * history of peptic ulcers * severe liver or gastro-intestinal disease within the last 6 months * injections or change in oral treatment regimen of glucosamine, chondroitin sulfate, hyaluronic acid, shark cartilage, or vitamin e within 3 months prior to screening * oral or parenteral corticosteroids within 3 months prior to screening * analgesic therapy for chronic or recurrent pain conditions for indications other than oa * immunosuppressants within 3 months prior to screening

Keywords: osteoarthritis; knee; idea-033
a study comparing two ferric carboxymaltose formulations in patients with iron deficiency anemia

Conditions: Iron Deficiency Anemia

Summary: this study will evaluate bioequivalence of two formulations of ferric carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.


Eligibility criteria:
inclusion criteria: * male and female patients at least 18 - 65 years of age; * patients with a body mass index (bmi) between 18.5 - 35 and with a body weight of ≥50 kg - ≤130 kg; exclusion criteria: * patients with known hypersensitivity to ferric carboxymaltose, excipients, or similar product * patients with chronic kidney disease who are on dialysis of any kind. * if female, is pregnant or nursing. * patients with blood loss leading to hemodynamic instability * patients with recent parenteral iron within 3 months prior to screening. other inclusion/exclusion criteria may apply.

Keywords: ferric carboxymaltose anemia
high flow nasal oxygen for acute hypoxemic respiratory failure in the emergency room

Conditions: Respiratory Distress Syndrome, Adult

Summary: the aim of this multicenter, randomized, controlled, open-label trial is to investigate the efficacy of early treatment with hfno compared with sot in preventing early deterioration of patients admitted to the er because of acute hypoxemic respiratory failure.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * pao2/fio2 ratio between 250 and 150 mmhg or spo2/fio2 ratio between 190 and 274, after at least 15 minutes of spontaneous breathing through a venturi mask (vm), with a fio2 targeted at a spo2 94-97%; * respiratory rate(rr)≤35breaths/min,afteratleast15minutesofspontaneous breathing through a vm, with a fio2 targeted at a spo2 94-97%; * paco2 ≤ 45 mmhg; * unilateral or bilateral infiltrate(s), as detected with chest radiography and/or computed tomography and/or with lung ultrasound not fully explained by effusions, atelectasis, or nodules/masses. infiltrates at lung ultrasound are defined as presence of focal b-lines, consolidations (with irregular marginal contour, air bronchogram, air trapping sign) and irregularity of the pleural line. exclusion criteria: * respiratory failure due to: * acute asthma or copd exacerbation, * cardiac failure or fluid overload as primary cause of respiratory failure; * unstable angina or ongoing acute myocardial infarction; * acute respiratory acidosis with ph \ 45 mmhg; * hemodynamic instability and/or use of vasopressors/inotropes; * altered mental status (kelly \>3), see figure 1;(18) * contraindications to niv (high risk of aspiration pneumonia, impaired airways protection, head-facial trauma and/or burns, uncooperative patient, cranial/thoracic/abdominal open wounds); * indications to urgent intubation performed according to the clinician in charge; * body mass index \> 35 kg/m2; * pregnancy; * patient's refusal to participate.
safety & efficacy of subretinal implants for partial restoration of vision in blind patients

Conditions: Retinal Degeneration; Retinitis Pigmentosa

Summary: patients who are legally blind, caused by retinal degeneration of photoreceptor rods \& cones (e.g. retinitis pigmentosa), receive a subretinal implant to restore vision partially.


Eligibility criteria:
inclusion criteria: * hereditary retinal degeneration of the outer retinal layers i.e. photoreceptor rods \& cones. * pseudophakia * angiography shows retinal vessels adequately perfused, despite pathological rp condition. * age between 18 and 78 years. * blindness (at least monocular) i.e. visual functions not appropriate for localization of objects, self sustained navigation and orientation (impaired light localization or worse). * ability to read normal print in earlier life, optically corrected without magnifying glass. * willing and able to give written informed consent in accordance to en iso 14155 (section 6.7) and local legislation prior to participation in the study. able to perform the study during the full time period of one year exclusion criteria: * period of appropriate visual functions \< 12 years / lifetime. * optical coherence tomography (oct) shows significant retina edema \&/or scar tissue within target region for implant. * retina detected as too thin to expect required rest-functionality of inner retina as shown via optical coherence tomography (oct). * lack of inner-retinal function, as determined by electrically evoked phosphenes (eep). * heavy clumped pigmentation at posterior pole * any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment). * amblyopia reported earlier in life on eye to be implanted * systemic diseases that might imply considerable risks with regard to the surgical interventions and anaesthesia (e.g. cardiovascular/ pulmonary diseases, severe metabolic diseases). * neurological and/or psychiatric diseases (e.g. m. parkinson, epilepsy, depression). * hyperthyroidism or hypersensitivity to iodine * women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study, or women unwilling to perform a pregnancy test before entering the study. * participation in another interventional clinical trial within the past 30 days.

Keywords: hereditary retinal degeneration outer retinal layers photoreceptor rods cones retinitis pigmentosa blindness reading ability retina implant subretinal
effect of d-cycloserine plus cognitive behavioral therapy on people with social phobia

Conditions: Social Anxiety Disorder

Summary: this study will assess the effectiveness of d-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.

social anxiety disorder (sad) is among the most common psychiatric conditions and is associated with significant distress and dysfunction in social situations. although treatment with cognitive-behavior therapy (cbt) is known to help remedy sad, many patients do not respond to this treatment and most do not reach full recovery. in cbt, patients undergo repeated and prolonged exposure practices to feared social situations to learn better ways to deal with anxiety in these settings. exposure therapy is based on animal models of extinction of conditioned fears, and recent animal research has identified some of the core pathways and neurotransmitters involved in fear extinction. d-cycloserine (dcs) is a drug that appears to facilitate learning and the process of extinction of conditioned fear in both animals and humans. this study will assess the effectiveness of dcs combined with cbt in treating people with sad. participants in this double-blind study will be randomly assigned to an active or control group. all participants will attend 18 study visits at the center for anxiety and related disorders over a 9-month period. there will be 12 cbt sessions of 90 minutes each and 6 assessment visits. the cbt sessions will help participants to become more comfortable with social situations. during 5 of the cbt sessions, participants will receive a pill containing either dcs or sugar (placebo). assessment visits will include interviews, self-report questionnaires, and laboratory tests. these visits will occur at weeks 1, 7, and 12 during treatment and at months 3, 6, and 9 post-treatment.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for generalized social anxiety disorder (gsad) * total score of greater than or equal to 60 on the lsas * physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities exclusion criteria: * lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders, or obsessive-compulsive disorder * eating disorder within the 6 months prior to study entry * history of organic brain syndrome, mental retardation, or other cognitive dysfunction * substance or alcohol abuse or dependence (other than nicotine) within the 6 months prior to study entry or inability to refrain from alcohol use during the acute period of study participation * post-traumatic stress disorder within 6 months prior to study entry; entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder * suicidal thoughts * taking concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) within 2 weeks of study entry * significant personality dysfunction * serious medical illness or instability for which hospitalization may be likely within the next year

Keywords: generalized subtype
scleral fixation for intraocular lens-bag dislocation

Conditions: Pseudoexfoliation Syndrome

Summary: novel introflective sutures offer a minimally invasive approach for stable fixation of dislocated bag-iol complexes, preserving visual acuity and reducing corneal complications in patients with pseudoexfoliation syndrome.

to assess the one-month outcomes of visual performance and positional stability of capsule-fixated intraocular lenses (iols) in patients with iol-bag complex dislocation. patients with intraoperative complications or prior posterior capsule nd-yag laser were excluded. surgical intervention involved creating a superior service keratotomy and using introflective sutures for iol fixation. best corrected visual acuity (bcva), endothelial cell counts, and tonometry were assessed at multiple postoperative time points. we also evaluated the mean spherical equivalent (se), and the residual cylinder and sphere at each follow-up.

Eligibility criteria:
inclusion criteria: * patients affected by pseudoexfoliation syndrome, with inferior dislocation of the bag-iol complex exclusion criteria: * patients who underwent intraoperative complications, * dislocation in the vitreous chamber of the bag-iol complex, * patients who had already undergone posterior capsule nd-yag laser
treatment as prevention for hepatitis c in iceland

Conditions: Hepatitis C

Summary: the main aim of this study is to test in the icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of hepatitis c with the aim of halting hcv (hepatitis c virus) transmission will lead to a reduction in incidence and disease burden associated with chronic hcv infection.

in iceland, a nationwide effort is planned where all patients with hcv infection will be offered treatment using direct acting antiviral agents. the aim of the initiative, besides offering cure to patients, is to substantially reduce domestic transmission of hcv and thereby lower the incidence. ultimately, with these intense efforts the long-term complications of chronic hcv infection could potentially be nearly eliminated. in iceland, there is mandatory reporting of all new cases of hepatitis c to the state epidemiologist. in the study, short term and long term outcomes of this initiative will be investigated. in an initial treatment phase which will last for up to three years, all patients diagnosed with hepatitis c in iceland will be offered treatment with direct acting antiviral agents. virological response rate and compliance will be monitored. long term, the incidence of hcv infection acquired in iceland will be monitored for up to 15 years, and the incidence rates of cirrhosis and hepatocellular carcinoma due to hcv will be monitored for up to 15 years.

Eligibility criteria:
inclusion criteria: * hcv positive subjects 18 years and older, living in iceland and covered by the icelandic health insurance. exclusion criteria: * age under 18 years * inability to sign informed consent.
the objectives of this study are study of the reactogenicity, safety and immunogenicity of flu-m inactivated split influenza vaccine in volunteers aged 18-60 years

Conditions: Influenza

Summary: study of the reactogenicity, safety and immunogenicity of flu-m inactivated split influenza vaccine in volunteers aged 18-60 years

all subjects will be followed up for 21 days post-randomization. the subjects will further be assessed at 2 days, 7 days, 21 days following the booster vaccination. blood samples will be collected for reactogenicity and safety and immunogenicity assessments before injection and 21 days after vaccination.

Eligibility criteria:
inclusion criteria: * written informed consent of the volunteers to participate in the clinical study; * healthy volunteers (men and women) aged 18-60 years; * volunteers with a titer of antibodies to a(h1n1), a(h3n2) and b influenza viruses less than 1:40 in a hi test * volunteers able to fulfill requirements of the protocol (i.e. fill out the patient's diary, come to follow-up visits); * female participants were obliged to have negative pregnancy test results and use contraceptives throughout the follow-up period (complete contraception for women of reproductive age) exclusion criteria: * allergic reactions to chicken protein or any previous influenza vaccination; * leukemia, cancer or a positive reaction to hiv infection, hepatitis b and c, syphilis in the medical history; * volunteers who received immunoglobulin or blood products within the last three months before the study; * guillain-barre syndrome (acute polyneuropathy) in the medical history; * long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the study; * any confirmed or suspected immunosuppressive or immunodeficiency condition; * respiratory, cardiovascular failure, impaired liver or kidney function found during a physical examination or laboratory tests at visit 1; * severe birth defects or serious chronic diseases, including any clinically significant chronic diseases of lungs, kidneys, cardiovascular, nervous system, psychiatric diseases or metabolic disorders, confirmed by medical history or objective examination; * volunteers who are (or were) patients of a tuberculosis dispensary and/or narcological dispensary and/or neuropsychiatric dispensary * acute infectious and/or non-infectious diseases at the time of inclusion in the study; * exacerbation of chronic diseases; * alcohol abuse and/or use of drugs in the past history; * pregnancy and lactation; * participation in another clinical study within the last 3 months

Keywords: influenza flu vaccine flu-m
what is the effect of aerobic exercise on depression in geriatric individuals diagnosed with depression?

Conditions: Aerobic Exercise; Depression; Geriatric; Chronic Illness

Summary: this study was planned to examine the effect of aerobic exercises on depression in geriatric individuals with a diagnosis of depression.

in this study 67 ± 5 years of age averaged and by the physician in geriatric depression diagnosis was placed 38 sedentary geriatric subjects were included. meet the inclusion criteria geriatric individuals information, vital signs (pulse,"beats /min", blood pressure, " mmhg ", respiration number, respiratory rate,) was recorded. depression levels, depression outcome scale- kofdss to and quality of life is quality of life survey -eurohis who-qol) were evaluated. 6-week, 4 days a week aerobic exercise program was applied to geriatric individuals. as aerobic exercise which included the heating and cooling cycle was started the first week and 120 minutes, 160 minutes weekend out and gradually the intensity was given as an exercise program to be increasing. individuals from the 6-week program were re-evaluated.

Eligibility criteria:
inclusion criteria: * 65-75 years of age a in range, geriatric depression diagnosed with and willing to participate in the study is when individuals were included in the study. exclusion criteria: * having geriatric psychiatric disorders other than depression, not being able to ride a bike for any reason, have contraindications for exercise, inability to adapt to exercise, not volunteering to participate

Keywords: aerobic exercise depression geriatric chronic illness
effect of endotracheal tube detection on pressure

Conditions: Pressure Injury

Summary: this study was conducted to examine the effect of two different tube detection on pressure wound formation in the intensive care unit. the search was carried out with a total of 60 patients that 30 of 60 them are interventions and 30 of 60 as experiments, who were hospitalized in the anesthesia and reanimation intensive care unit of an educational research hospital. the 60 patients who made up the sample were assigned 2 groups using a computer program that produced random numbers. for the purpose of the study, the groups were encoded as groups a and b, and each group was tested with two different endotracheal tube detection methods which was applied to the patients in the groups. data from the study were collected using the introductory and clinical features form, the braden pressure wound risk diagnostic scale, the pressure ulcer recovery assessment scale, the international pressure wound staging system, and the eilers oral assessment guide. patients in both groups were monitored for four days for oral presure injury. during this process, the tube detection of both groups was changed every 24 hours, and the tubes were repositioned every 4 hours. at the end of the fourth day, wound assesments of patients who developed pressure wounds were performed by using the international pressure staging system and the pressure ulcer recovery assessment scale. relatives of the patients who were scheduled to conduct the study were informed about the study by oral and written and their consent was obtained.


Eligibility criteria:
inclusion criteria: * must be between the ages of 18-65 * must be intubated oratraceal exclusion criteria: * oral pressure wounds * burns on the face * diabetes * facial and neck trauma

Keywords: endotracheal tube endotracheal tube holder bandage intensive care unit pressure wound
pain in individuals with copd during pulmonary rehabilitation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study is aimed at determining the role of pain in individuals with chronic obstructive pulmonary disease (copd) who are enrolled in a pulmonary rehabilitation (pr) program. it is not known whether pain interferes with an individuals performance in pr, or whether pr aggravates or relieves pain. individuals with copd who report chronic pain and those without pain will be enrolled in the study.

chronic obstructive pulmonary disease (copd) is a systemic disease associated with dyspnea, fatigue, and poor health-related quality of life. copd is further complicated by the presence of pain which may be attributed to common comorbidities such as musculoskeletal conditions (osteoarthritis, osteoporosis), cardiac disease or diabetes. pulmonary rehabilitation (pr) is the cornerstone of treatment for copd however the impact of pain on pr has not been explored. it is unclear whether those experiencing chronic pain achieve a similar, lesser or greater degree of benefit compared to those without pain, or whether exercise training exacerbates symptoms. gaining a greater understanding of the effects of an outpatient pr program on pain will provide direction into future specific treatment options which may necessary for managing chronic pain as part of pr. individuals with copd who are beginning an out-patient pr program will be enrolled in the study. those who report the presence of chronic pain will be classed as the pain group; those who report the absence of chronic pain will be classed as the comparator group. all participants will complete a 6-minute walk test and a chronic respiratory disease questionnaire (crdq) at the beginning of the pr program. these measures will be repeated at the end of the 8-week pr program for all participants. all participants will be asked to report their level of pain using a visual analogue scale every two weeks during the pr program. participants reporting chronic pain will also complete a series of questionnaires regarding their pain and coping strategies. these include; the brief pain inventory (bpi), coping strategies questionnaire (csq), fear avoidance behavior questionnaire (fabq), hospital anxiety and depression scale (hads) and centre for epidemiological studies for depression survey (ces-d).

Eligibility criteria:
inclusion criteria: * individuals with moderate to severe copd based on international (gold) criteria * clinically stable * no history of acute exacerbation in the past 6 weeks * able to provide their own informed consent * referred to out-patient pulmonary rehabilitation at west park healthcare centre exclusion criteria: * primary diagnosis other than copd * known cognitive impairment that would interfere with completing surveys * cardiac, neurological or orthopedic conditions which prevent the ability to undertake exercise safely